Compare KIDS & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KIDS | IRWD |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 588.8M | 578.3M |
| IPO Year | 2016 | 2009 |
| Metric | KIDS | IRWD |
|---|---|---|
| Price | $31.63 | $4.38 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 4 |
| Target Price | ★ $30.75 | $6.10 |
| AVG Volume (30 Days) | 413.0K | ★ 1.6M |
| Earning Date | 10-27-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.91 |
| Revenue | $98,049,000.00 | ★ $298,276,000.00 |
| Revenue This Year | $14.33 | $59.19 |
| Revenue Next Year | $12.13 | $4.80 |
| P/E Ratio | ★ N/A | $7.00 |
| Revenue Growth | ★ 37.95 | 8.88 |
| 52 Week Low | $14.42 | $2.31 |
| 52 Week High | $34.53 | $5.78 |
| Indicator | KIDS | IRWD |
|---|---|---|
| Relative Strength Index (RSI) | 70.30 | 69.47 |
| Support Level | $15.56 | $3.99 |
| Resistance Level | N/A | $4.53 |
| Average True Range (ATR) | 1.72 | 0.20 |
| MACD | 0.70 | 0.10 |
| Stochastic Oscillator | 77.32 | 95.75 |
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercializes implants and instruments to meet the needs of surgeons and patients. Its products include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia, and ACL Reconstruction System, among others. The company operates in one operating and reportable segment, OrthoPediatrics, which designs, develops, and markets anatomically appropriate specialized braces, implants, and devices for children with orthopedic problems.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.